AllPennyStocks.com QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside

uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.

Other Penny Stock Movers

From Bitcoin to Big League Sports
Canadian Gold Explorer Gains 17% as Final Assays Complete Maiden Resource Database
Nevada Gold Explorer Surges 21% on Broad High-Grade Drill Intercepts
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top